Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
Status: | Completed |
---|---|
Conditions: | Psoriasis, Dermatology |
Therapuetic Areas: | Dermatology / Plastic Surgery |
Healthy: | No |
Age Range: | 18 - 55 |
Updated: | 4/21/2016 |
Start Date: | November 2010 |
End Date: | April 2012 |
Double-blind, Randomized, Vehicle-controlled, Multicenter, Multinational, Parallel-group Study of the Efficacy and Safety of ZK245186 Ointment in Concentrations of 0.01, 0.03, and 0.1% Over 4 Weeks in Patients With Atopic Dermatitis (AD)
The purpose of this study is to evaluate the efficacy and safety of three concentrations of
a development drug compared to placebo in the treatment of atopic dermatitis.
a development drug compared to placebo in the treatment of atopic dermatitis.
Inclusion Criteria:
- Diagnosis of atopic dermatitis according to Hanifin and Rajka criteria
- Body surface area affected by atopic dermatitis at or less than 15% at start of
treatment
Exclusion Criteria:
- Pregnancy and breast-feeding
- Conditions that may pose a threat to the patient or effect the outcome of the study
- Wide-spread atopic dermatitis (AD) requiring systemic treatment
- Immuno-compromized conditions
- At least 2 weeks after local AD treatment and treatment with systemic antibiotics
- At least 1 month after systemic AD treatment
We found this trial at
14
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials